SUBSCRIBE
SUBSCRIBE

GLP-1

Biotech Bay
How Weight-Loss Surgery Reverses Type 2 Diabetes: University of California, Davis (UCD) New Study Offers Explanation
March 25, 2010
 · 
6 min read
Obesity And Type 2 Diabetes Market Closely Linked But Vastly Different In Outlook
March 10, 2010
 · 
3 min read
Drug Development
Novo Nordisk A/S New Diabetes Drug Liraglutide Works Well In Trial; Could Be Approved For U.S. Market By Next Year, Baylor College of Medicine Researcher Says
September 25, 2008
 · 
3 min read
WuXi PharmaTech Co., Ltd. and Covance Inc. Will Partner in JV
June 25, 2008
 · 
1 min read
Business
The Week in Review: Anesiva, Inc. Forms JV with Fosun Pharma
October 15, 2007
 · 
1 min read
Business
WuXi PharmaTech Co., Ltd. Begins Building GLP Center in Suzhou
October 9, 2007
 · 
1 min read
Business
ConjuChem
October 19, 2005
 · 
8 min read
Load More
PRESS RELEASES
Press Releases
RO LAUNCHES WEGOVY® PILL THROUGH INTEGRATION WITH NOVO NORDISK
January 5, 2026
 · 
3 min read
Press Releases
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
January 5, 2026
 · 
4 min read
Press Releases
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways
December 29, 2025
 · 
19 min read
Press Releases
FDA approves Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
December 23, 2025
 · 
14 min read
Press Releases
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
December 23, 2025
 · 
4 min read
Press Releases
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
December 19, 2025
 · 
9 min read
Press Releases
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
December 18, 2025
 · 
24 min read
Press Releases
Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia
December 18, 2025
 · 
4 min read
Press Releases
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
December 18, 2025
 · 
15 min read
Press Releases
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
December 17, 2025
 · 
21 min read
Press Releases
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
December 12, 2025
 · 
5 min read
Press Releases
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
December 11, 2025
 · 
5 min read
Press Releases
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
December 8, 2025
 · 
14 min read
Press Releases
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
December 8, 2025
 · 
12 min read
Press Releases
Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
December 8, 2025
 · 
7 min read
Press Releases
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
December 8, 2025
 · 
1 min read
Press Releases
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
December 2, 2025
 · 
10 min read
Press Releases
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
December 1, 2025
 · 
4 min read
Press Releases
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
November 27, 2025
 · 
3 min read
Press Releases
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096
November 27, 2025
 · 
6 min read
Load More